Comparative Pharmacology
Head-to-head clinical analysis: BENADRYL PRESERVATIVE FREE versus SEMPREX D.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENADRYL PRESERVATIVE FREE versus SEMPREX D.
BENADRYL PRESERVATIVE FREE vs SEMPREX-D
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Diphenhydramine competitively antagonizes histamine at H1-receptors on effector cells, leading to relief of allergic symptoms. It also possesses anticholinergic, antiemetic, sedative, and local anesthetic effects.
SEMPREX-D combines acrivastine, a histamine H1 receptor antagonist, and pseudoephedrine, a sympathomimetic amine vasoconstrictor. Acrivastine blocks peripheral histamine-mediated effects, while pseudoephedrine constricts nasal blood vessels to reduce congestion.
25-50 mg IV/IM every 4-6 hours as needed; maximum single dose 100 mg, maximum daily dose 400 mg.
1 capsule orally every 12 hours; each capsule contains acrivastine 8 mg and pseudoephedrine 60 mg.
None Documented
None Documented
Terminal elimination half-life: 4-8 hours (mean ~5 hours). Prolonged in hepatic impairment (up to 2-fold) and elderly (7-12 hours).
Terminal elimination half-life is approximately 8-12 hours, allowing twice-daily dosing.
Primarily renal (90% as metabolites and unchanged drug); ~1% excreted in feces via bile. Unchanged diphenhydramine accounts for <5% of urinary recovery.
Renal (approx. 60% as unchanged drug and metabolites), biliary/fecal (approx. 40%).
Category C
Category C
Antihistamine
Antihistamine/Decongestant Combination